Hubei Guangji Pharmaceutical Co., Ltd.

Symbol: 000952.SZ

SHZ

6.12

CNY

Market price today

  • -14.2334

    P/E Ratio

  • -0.0163

    PEG Ratio

  • 2.10B

    MRK Cap

  • 0.00%

    DIV Yield

Hubei Guangji Pharmaceutical Co., Ltd. (000952-SZ) Financial Statements

On the chart you can see the default numbers in dynamics for Hubei Guangji Pharmaceutical Co., Ltd. (000952.SZ). Companys revenue shows the average of 470.101 M which is 0.079 % gowth. The average gross profit for the whole period is 170.696 M which is 0.215 %. The average gross profit ratio is 0.353 %. The net income growth for the company last year performance is -3.786 % which equals -2.383 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Hubei Guangji Pharmaceutical Co., Ltd., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.227. In the realm of current assets, 000952.SZ clocks in at 1084.666 in the reporting currency. A significant portion of these assets, precisely 415.244, is held in cash and short-term investments. This segment shows a change of -0.037% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 45.355, if any, in the reporting currency. This indicates a difference of 2.773% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 419.537 in the reporting currency. This figure signifies a year_over_year change of 0.546%. Shareholder value, as depicted by the total shareholder equity, is valued at 1363.446 in the reporting currency. The year over year change in this aspect is -0.093%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 350.696, with an inventory valuation of 298.99, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 216.91. Account payables and short-term debt are 143.02 and 516.32, respectively. The total debt is 935.86, with a net debt of 520.62. Other current liabilities amount to 90.93, adding to the total liabilities of 1637.07. Lastly, the referred stock is valued at 0.01, if it exists.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996

balance-sheet.row.cash-and-short-term-investments

2401.91415.2431.4293.3
350.3
183.7
173.6
140.8
116.7
161.9
194.8
111
125
152.3
211.8
188.8
220.1
172.2
72.6
32.1
45.7
69.1
135.8
95.5
117.1
113.2
6.9
2.9
2.8

balance-sheet.row.short-term-investments

-21.47-10.200
-0.1
-0.4
-0.5
-0.5
0
0
0
0
0
0
0
0
0
0.3
10.5
10
10
11
0
0
25
30
0
0
0

balance-sheet.row.net-receivables

1407.13350.7339.9238.5
169.6
172.3
177.4
161.7
167.1
139.4
76.7
231.9
134
149
180.3
245.2
257.7
202.5
209.8
381.2
389.2
390.7
201.8
205.1
41.2
24.9
17.5
4.7
8.1

balance-sheet.row.inventory

1249.74299221.5164.8
163.6
137.9
98.5
98.4
109.2
98.9
151.5
170.8
181.9
203.7
97.6
52.4
91.4
60.7
50.9
60
62.4
61.8
59.9
59.6
48.8
55.6
84.5
78
41.6

balance-sheet.row.other-current-assets

68.4219.712.712.3
18.6
20.4
19.1
19.7
23.2
32.6
55
-63
-25.1
-24.1
-32.9
-46.5
-43.3
0.7
-44.3
-106.8
-108
-125.5
2
9.4
127.8
138.7
126.8
100.6
56.9

balance-sheet.row.total-current-assets

5127.211084.71005.5709
702.1
514.3
468.6
420.5
416.3
432.8
477.9
450.8
415.8
481
456.8
439.9
526
436
288.9
366.5
389.3
396
399.4
369.6
334.9
332.5
235.6
186.3
109.3

balance-sheet.row.property-plant-equipment-net

5756.251637.11199.21069.2
1041.9
963.4
959.5
969.3
974.5
942.5
854.6
858.4
863.8
865.8
780.5
684.9
502.9
376.5
336.8
353.2
352.5
325.4
277.5
256.6
218.8
223.3
107
108.3
96.7

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

728.73216.9150.6154.7
161.6
168.5
165.5
169.3
183
191.8
193.5
196.9
190.9
75
62.6
65
83.9
53.7
38.6
41.9
45.5
49.8
53.2
47.3
37.5
36.6
34.3
36.5
37

balance-sheet.row.goodwill-and-intangible-assets

728.73216.9150.6154.7
161.6
168.5
165.5
169.3
183
191.8
193.5
196.9
190.9
75
62.6
65
83.9
53.7
38.6
41.9
45.5
49.8
53.2
47.3
37.5
36.6
34.3
36.5
37

balance-sheet.row.long-term-investments

167.1945.444.139.8
22.8
27.8
32.1
34.5
0
0
0
0
0
77.9
0
0
0
107.3
108.2
108.1
109.1
78.3
0
0
58.8
23.6
0
0
0

balance-sheet.row.tax-assets

90.7315.926.824.8
21.8
17.6
18.6
21.5
0
0
0
6.5
5.1
6.9
6.2
7.6
12.5
25
11.9
12.2
12.9
14.7
0
0
25.5
32
0
0
0

balance-sheet.row.other-non-current-assets

59629.642.851.4
29.4
74.9
49
26.7
60.1
53.6
56.4
39.2
80.4
0
78.4
106.4
81.8
0.3
0.6
0.6
2.6
2.6
89.7
88.3
0.7
0.8
1.8
2
1.9

balance-sheet.row.total-non-current-assets

7338.91944.91463.61339.9
1277.4
1252.2
1224.7
1221.4
1217.6
1187.9
1104.5
1101
1140.2
1025.7
927.6
864
681.1
562.8
496.1
516
522.7
470.9
420.5
392.2
341.3
316.3
143.1
146.8
135.6

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

12466.113029.52469.12048.9
1979.4
1766.5
1693.3
1641.9
1633.9
1620.7
1582.5
1551.8
1556
1506.7
1384.4
1303.8
1207.1
998.8
785
882.4
912
866.9
819.9
761.8
676.2
648.8
378.8
333
244.9

balance-sheet.row.account-payables

542.15143178.6121.6
139.1
104.4
103.2
118.5
162.8
254.2
290.6
332.4
307.4
161.5
96.1
98.5
90.1
54.6
51.8
40
66
62.3
59.1
50.6
42.2
18.9
22.3
39.3
4.4

balance-sheet.row.short-term-debt

2189.84516.3357.2336.7
219.4
521.7
524.4
531.4
506.9
207.7
189
202.2
251.5
264
207.1
135
81
68
135
192
208.2
178.2
175.2
149.8
45.4
79.4
125.4
62
46.5

balance-sheet.row.tax-payables

43.6412.117.613.6
18.6
7.2
14.2
29.8
17.6
9
13.6
-28.6
-34
-30.9
-16.7
-5.7
96.4
112
-3.3
-5.5
-7.8
-4.3
-7
-0.9
7.6
9.5
3.4
0.3
-0.3

balance-sheet.row.long-term-debt-total

1740.97419.5248.136.1
84.4
74.8
27.5
80.5
132.6
308
317
79.5
124.6
103.5
121.8
142.7
0
10
77.5
72
83.2
73
50
40
69
48
7.1
38
36.5

Deferred Revenue Non Current

63.7915.718.121
23.3
25.8
27.5
31.3
34.4
43.6
49.7
47.9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

751.08---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

305.0590.9112.70.9
2.6
5.7
86.2
20.9
28.8
15.8
31.1
15.3
14.6
8.8
11.4
11.6
7.8
13.7
15.3
14.5
11.6
14.5
15.4
9.6
5.6
2.8
0.1
6.3
0.1

balance-sheet.row.total-non-current-liabilities

3276.47771.2323.257.8
153.3
100.6
84.3
113.9
179.7
545.8
383.1
127.5
158.8
122.6
140.5
158.2
16.8
10
77.5
79.1
84.1
73.5
50.1
40.1
69.1
51.1
10.8
41.1
39.2

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

9.862.23.21.6
0
27
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

6780.931637.1977.2598.1
613.7
802.2
812.3
876.6
974.7
1106.9
1077
816.8
795.9
643.1
545.1
486.9
395.8
325.8
307.3
350.7
388.8
352.4
313
275
194.7
199.5
186.8
166.8
110.7

balance-sheet.row.preferred-stock

0.01000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

1415.67353.9354344
347
251.7
251.7
251.7
251.7
251.7
251.7
251.7
251.7
251.7
251.7
251.7
251.7
251.7
251.7
171.2
171.2
171.2
171.2
171.2
171.2
171.2
121.2
121.2
86.6

balance-sheet.row.retained-earnings

2151.24502.7644.6626.9
554.4
584.9
505.8
368.4
265.7
123.9
102.9
321.7
319.3
414.8
412.3
401.7
363.1
308.4
139.3
125.3
118
111
104.4
87.6
84.3
56.8
44.7
22.8
30.2

balance-sheet.row.accumulated-other-comprehensive-income-loss

754.230158.5172.2
155.4
127.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

1286.99506.9345.6319.3
316.4
-3.8
115.7
139.2
136.6
136.6
143.5
143.5
148
149.5
142.4
139.1
133.4
107.1
86.2
234.9
233.6
232.3
231.2
228.1
226
221.3
26
22.2
17.4

balance-sheet.row.total-stockholders-equity

5608.141363.41502.61462.5
1373.1
960.4
873.3
759.2
654
512.2
498.2
716.9
718.9
816
806.5
792.5
748.3
667.2
477.3
531.3
522.8
514.6
506.9
486.9
481.5
449.3
192
166.2
134.2

balance-sheet.row.total-liabilities-and-stockholders-equity

12466.113029.52469.12048.9
1979.4
1766.5
1693.3
1641.9
1633.9
1620.7
1582.5
1551.8
1556
1506.7
1384.4
1303.8
1207.1
998.8
785
882.4
912
866.9
819.9
761.8
676.2
648.8
378.8
333
244.9

balance-sheet.row.minority-interest

77.0529-10.8-11.7
-7.4
3.9
7.7
6
5.2
1.7
7.3
18.1
41.1
47.6
32.9
24.4
63
5.8
0.4
0.4
0.4
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

5685.191392.41491.81450.8
1365.7
964.3
881
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

12466.11---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

145.7235.244.139.8
22.6
27.4
31.6
34
35.5
38.9
39.4
39
80.4
78
78.4
106.4
81.8
107.6
118.7
118.1
119.1
89.3
87
87.4
83.8
53.6
0
0
0

balance-sheet.row.total-debt

3930.81935.9605.4372.8
303.8
596.5
551.9
531.4
506.9
515.7
506
281.7
376.1
367.5
329
277.7
81
78
212.5
264
291.4
251.2
225.2
189.8
114.4
127.4
132.5
100
82.9

balance-sheet.row.net-debt

1528.9520.617479.5
-46.5
412.8
378.4
390.5
390.2
353.8
311.2
170.7
251.1
215.2
117.2
88.9
-139.1
-94.2
150.4
241.9
255.7
193.1
89.4
94.3
22.3
44.2
125.7
97
80.1

Cash Flow Statement

The financial landscape of Hubei Guangji Pharmaceutical Co., Ltd. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -3.508. The company recently extended its share capital by issuing 0, marking a difference of -0.032 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 29.87 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to -121737831.980 in the reporting currency. This is a shift of 0.067 from the previous year. In the same period, the company recorded 98.31, -3.49, and -415.44, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -40.24 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 756.62, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998

cash-flows.row.net-income

-146.7247.7105.870.3
83.2
173.4
106.1
145.3
18.4
-229.6
-5
-103.5
0.8
9.4
37.2
97.3
195.6
15.7
8.6
8.1
7.7
19.9
24.6
30.6
31.4
25.7

cash-flows.row.depreciation-and-amortization

94.6398.391.390.4
81.3
82.8
82.5
73.1
54.4
68.2
66.9
62.2
58.8
52.8
37.9
34.2
30.4
30.8
28.1
23.9
22.5
19.3
20.3
12.2
14
11.9

cash-flows.row.deferred-income-tax

-0.1-2.3-2.7-4.1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

7.289.52.74.1
-1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

-152.33-138.8-121.4-50.9
-61.9
-63.2
-78.5
-99.1
-171.8
-24.1
32.4
115.4
-1.6
1.9
-85.6
67.1
50.1
44.3
-4.8
-50.4
-64.8
24.4
-87.4
6.3
9.8
-53.6

cash-flows.row.account-receivables

-53.06-102.1-66.9475.9
2.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-100.18-64.3-4.3-26.8
-43
3.1
10.9
-11.5
48.2
-5.5
10.5
23.4
-109.4
-46.7
38
-30.7
0.4
9.2
0.9
-0.6
-1.9
-0.5
10.8
6.4
28.2
-6.5

cash-flows.row.account-payables

029.9-47.4-495.7
-22.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0.91-2.3-2.7-4.1
1
-66.4
-89.3
-87.6
-220
-18.6
21.9
92
107.7
48.6
-123.6
97.8
49.7
35.1
-5.7
-49.8
-62.9
24.9
-98.2
-0.1
-18.4
-47.1

cash-flows.row.other-non-cash-items

70.3430.70.29.5
41.7
38.4
68.7
47.8
65.6
110.8
0.9
33.9
23.9
13.1
-13.8
22
55.8
35.2
22.3
15
19.2
12.6
20.1
-0.5
13.3
0.6

cash-flows.row.net-cash-provided-by-operating-activities

-134.19000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-559.78-203.7-96.6-97.9
-119.8
-76.5
-80.9
-112.9
-109.9
-94.6
-50
-117.5
-201
-115.6
-149.9
-219.8
-48.9
-18.7
-25.8
-47.6
-65.7
-50.5
-46.8
-25.1
-135.6
-3

cash-flows.row.acquisitions-net

523.50.741.4
0.1
0
0
0
110
1.2
59.8
117.7
12.4
13
13.3
0.1
-1.2
0
26
47.6
66.1
0
0
25.6
0
0

cash-flows.row.purchases-of-investments

0-10-80-830
-0.1
0
0
0
-10
-34
-2
-8
-7
-8
-67.6
-15
-29.6
-2.3
-0.9
-13
-20.4
-2
-9
-21.6
-83.6
0

cash-flows.row.sales-maturities-of-investments

-749261.8773.5
0.1
0.2
0.2
2.5
0.3
38.4
37.5
7.1
8
12.3
10.4
10
1.5
0
1.9
13
10
0
26
8
0
0

cash-flows.row.other-investing-activites

0.35-3.500.2
0.1
0.1
1
1.4
-109.9
10
-50
-117.5
16.3
2.5
0.5
56
0.4
0.1
-25.8
-47.6
-65.7
0.6
10
-25.1
0.5
0

cash-flows.row.net-cash-used-for-investing-activites

-559.42-121.7-114.1-112.8
-119.5
-76.2
-79.7
-109.1
-119.6
-79
-4.8
-118.1
-171.3
-95.7
-193.3
-168.7
-77.8
-21
-24.7
-47.5
-75.8
-51.9
-19.8
-38.2
-218.6
-3

cash-flows.row.debt-repayment

-344-415.4-399.5-680.1
-563.9
-495.7
-476
-148
-272.7
-357.1
-355.8
-356.2
-326.5
-177.7
-150
-102
-226.5
-205.3
-168.2
-154.7
-190.2
-37.9
-47.4
-51.1
-53.1
-21.7

cash-flows.row.common-stock-issued

000-5.9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

0005.9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

-36.9-40.2-35.7-49.5
-29.3
-50.9
-31.8
-35.5
-36.1
-21.2
-26.4
-25.8
-21.1
-12.8
-6.2
-26.7
-10.4
-13.5
-15.7
-11.8
-12.5
-19.4
-9.6
-13.1
-12.5
-10.9

cash-flows.row.other-financing-activites

931.87756.6388.4832.7
576.5
424.2
440
87.7
423.7
619.6
261.4
364.8
377.5
232
342.6
124.7
92
153.8
140.8
194.9
216.2
73.3
102.6
62.7
292.1
54.8

cash-flows.row.net-cash-used-provided-by-financing-activities

707.19300.9-46.8103.1
-16.8
-122.4
-67.8
-95.9
114.9
241.2
-120.8
-17.2
29.9
41.5
186.4
-4.1
-144.9
-65
-43.1
28.4
13.5
16
45.6
-1.5
226.4
22.2

cash-flows.row.effect-of-forex-changes-on-cash

0.781.4-1.5-3.8
2.2
-0.1
2.8
0.1
0.2
0
0
0
0
0
0
0
0
0
0.1
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

14.36225.7-86.5105.9
10.1
32.7
34.2
-37.7
-37.8
87.5
-30.4
-27.3
-59.4
22.9
-31.3
47.9
109.3
40
-13.5
-22.4
-77.7
40.3
3.4
8.9
76.4
4

cash-flows.row.cash-at-end-of-period

2397.91428.8203.1289.5
183.7
173.6
140.8
106.7
144.4
182.2
94.6
125
152.3
211.8
188.8
220.1
172.2
62.1
22.1
35.7
58.1
135.8
95.5
92.1
83.2
6.9

cash-flows.row.cash-at-beginning-of-period

2383.56203.1289.5183.7
173.6
140.8
106.7
144.4
182.2
94.6
125
152.3
211.8
188.8
220.1
172.2
62.9
22.1
35.7
58.1
135.8
95.5
92.1
83.2
6.9
2.9

cash-flows.row.operating-cash-flow

-134.1945.175.9119.4
144.2
231.4
178.8
167.1
-33.3
-74.7
95.2
108
81.9
77.2
-24.3
220.7
332
126
54.1
-3.3
-15.4
76.2
-22.4
48.6
68.6
-15.3

cash-flows.row.capital-expenditure

-559.78-203.7-96.6-97.9
-119.8
-76.5
-80.9
-112.9
-109.9
-94.6
-50
-117.5
-201
-115.6
-149.9
-219.8
-48.9
-18.7
-25.8
-47.6
-65.7
-50.5
-46.8
-25.1
-135.6
-3

cash-flows.row.free-cash-flow

-693.96-158.6-20.721.5
24.4
154.9
97.9
54.1
-143.3
-169.3
45.1
-9.4
-119.1
-38.4
-174.3
0.9
283
107.2
28.3
-50.9
-81.1
25.7
-69.2
23.5
-67
-18.2

Income Statement Row

Hubei Guangji Pharmaceutical Co., Ltd.'s revenue saw a change of -0.075% compared with the previous period. The gross profit of 000952.SZ is reported to be 202.2. The company's operating expenses are 275.42, showing a change of 31.791% from the last year. The expenses for depreciation and amortization are 98.31, which is a 0.220% change from the last accounting period. Operating expenses are reported to be 275.42, which shows a 31.791% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -2.445% year-over-year growth. The operating income is -141.05, which shows a -2.445% change when compared to the previous year. The change in the net income is -3.786%. The net income for the last year was -140.25.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996

income-statement-row.row.total-revenue

802.69737.8797.6837.1
688.2
731.3
843.8
801.6
714.7
560.4
485.9
487.1
394.2
453.3
483.3
448.2
571.8
794.9
388.7
345.8
276.6
204.1
202.2
186.1
134.1
176.6
161.3
141.2
114.9

income-statement-row.row.cost-of-revenue

592.07535.6502.5535.9
408.5
391.5
364.4
393.6
341.7
379.3
440.5
427.2
380.6
359.4
388.6
353.9
341.2
337.9
271.5
260.9
209.1
130.8
127.3
105.5
68.8
98.2
89.3
71.1
68.6

income-statement-row.row.gross-profit

210.62202.2295.1301.2
279.6
339.8
479.5
407.9
373
181.1
45.3
59.9
13.6
93.9
94.7
94.3
230.6
457
117.2
85
67.5
73.3
74.9
80.6
65.4
78.4
72
70.2
46.3

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

74.42---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

93.38---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

39.31---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

1.890.46257.5
53.8
42.3
-4.1
-13.7
-1.3
17
5.6
51.6
17.3
7.1
11.5
2.8
3.2
0.8
-8.4
-2
-0.5
0.2
0
-0.2
-0.1
9.8
-0.3
0.1
0.1

income-statement-row.row.operating-expenses

290.39275.4209185.4
172.6
203.3
228
198
171
116.7
155.9
107.8
94.6
75.5
76
68.9
99.8
125.1
69.7
49
40.9
41
36.6
31.9
25.6
32.1
30.3
23.9
18.9

income-statement-row.row.cost-and-expenses

882.46811711.5721.2
581.2
594.8
592.3
591.6
512.7
496
596.4
535
475.2
434.9
464.6
422.7
441
463
341.2
309.9
250
171.8
163.9
137.4
94.4
130.3
119.6
95
87.5

income-statement-row.row.interest-income

3.43.523.2
1.4
1.1
0.6
0.7
1.3
2.6
2.6
2.2
1.2
5.5
1.2
0
2.8
1.1
0.3
0.3
0.3
0.4
1.2
0.8
0.8
0
0
0
0

income-statement-row.row.interest-expense

52.9549.221.116.7
32.6
35.1
30.7
33.7
36.3
35.8
25
28.8
24.9
21.1
12.8
4.6
5
10.9
13.5
15.9
11.8
11.7
11.5
9.2
5.8
12.1
10.9
11.3
8.3

income-statement-row.row.selling-and-marketing-expenses

39.31---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

1.890.4-37.56.1
-8.7
-37.1
-44.5
-88.4
-46.4
-46
-112.5
41.5
-21
-14.2
-3.1
18.1
-13.3
-49.3
-21.9
-19.7
-13.9
-14.2
-10.9
-16.6
-3.1
-2.3
-11.3
-11.2
-8.8

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

1.890.46257.5
53.8
42.3
-4.1
-13.7
-1.3
17
5.6
51.6
17.3
7.1
11.5
2.8
3.2
0.8
-8.4
-2
-0.5
0.2
0
-0.2
-0.1
9.8
-0.3
0.1
0.1

income-statement-row.row.total-operating-expenses

1.890.4-37.56.1
-8.7
-37.1
-44.5
-88.4
-46.4
-46
-112.5
41.5
-21
-14.2
-3.1
18.1
-13.3
-49.3
-21.9
-19.7
-13.9
-14.2
-10.9
-16.6
-3.1
-2.3
-11.3
-11.2
-8.8

income-statement-row.row.interest-expense

52.9549.221.116.7
32.6
35.1
30.7
33.7
36.3
35.8
25
28.8
24.9
21.1
12.8
4.6
5
10.9
13.5
15.9
11.8
11.7
11.5
9.2
5.8
12.1
10.9
11.3
8.3

income-statement-row.row.depreciation-and-amortization

72.0912098.3114.7
119.6
81.3
82.8
82.5
73.1
54.4
68.2
66.9
62.2
58.8
52.8
37.9
34.2
30.4
30.8
28.1
23.9
22.5
19.3
20.3
12.2
14
11.9
10.6
7.9

income-statement-row.row.ebitda-caps

-79.85---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-151.94-141.197.6118.2
96.8
137
211.1
135.3
159.2
21.9
-226.5
-58.1
-118.7
-2.8
5.3
40.8
114.3
281.7
33.8
18.2
13.2
17.9
27.3
32.3
37
34.2
30.8
35.6
19.5

income-statement-row.row.income-before-tax

-150.05-140.760.1124.3
88.1
99.9
207.1
121.6
155.6
18.4
-223.1
-6.4
-102
4.2
15.6
43.6
117.5
282.6
25.5
16.2
12.7
18.1
27.3
32.1
36.8
44
30.4
35.4
19.1

income-statement-row.row.income-tax-expense

11.6311.712.418.5
17.8
16.7
33.7
15.5
10.3
0
6.5
-1.5
1.6
3.4
6.2
6.4
29.9
99.8
9.8
7.7
4.5
10.4
7.4
7.5
6.1
12.6
4.7
3.3
1.7

income-statement-row.row.net-income

-146.72-140.250.3110.1
74.6
86.9
171.7
105.2
141.8
20.9
-218.7
2.4
-95.6
4.8
14
43
89.1
183.8
15.7
8.6
8.2
7.7
19.9
24.6
30.6
31.4
25.7
32
17.4

Frequently Asked Question

What is Hubei Guangji Pharmaceutical Co., Ltd. (000952.SZ) total assets?

Hubei Guangji Pharmaceutical Co., Ltd. (000952.SZ) total assets is 3029517090.000.

What is enterprise annual revenue?

The annual revenue is 395486306.000.

What is firm profit margin?

Firm profit margin is 0.262.

What is company free cash flow?

The free cash flow is -1.961.

What is enterprise net profit margin?

The net profit margin is -0.183.

What is firm total revenue?

The total revenue is -0.189.

What is Hubei Guangji Pharmaceutical Co., Ltd. (000952.SZ) net profit (net income)?

The net profit (net income) is -140248068.540.

What is firm total debt?

The total debt is 935859479.000.

What is operating expences number?

The operating expences are 275418481.000.

What is company cash figure?

Enretprise cash is 403741511.000.